Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus.
Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous thromboembolism (VTE) and major bleeding complications. Risks vary significantly between individuals based on cancer status, treatment, and other characteristics. To facilitate the evidence-based management of anti...
| Publicado en: | Current Oncology Vol. 28; no. 6; pp. 5434 - 5452 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Dec2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=154401459&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 154401459 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Dec2021 vid: 28 iid: 6 pid: 97109 pub: MDPI artinfo: ui: 154401459 10.3390/curroncol28060453 154401459 ppf: 5434 ppct: 18 formats: fmt: @attributes: type: P tig: atl: Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. aug: au: Carrier, Marc Blais, Normand Crowther, Mark Kavan, Petr Le Gal, Grégoire Moodley, Otto Shivakumar, Sudeep Suryanarayan, Deepa Tagalakis, Vicky Cynthia Wu Lee, Agnes Y. Y. affil: Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa Ottawa, ON K1H 8L6, Canada sug: ab: Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous thromboembolism (VTE) and major bleeding complications. Risks vary significantly between individuals based on cancer status, treatment, and other characteristics. To facilitate the evidence-based management of anticoagulant therapy in this patient population, a committee of 11 Canadian clinical experts updated a consensus-based algorithm for the acute and extended treatment of symptomatic and incidental CAT that was developed in 2018. Following a systematic review of the literature, updates to the algorithm were discussed during an online teleconference, and the algorithm was subsequently refined based on feedback from committee members. Clinicians using this treatment algorithm should consider bleeding risk, type of cancer, and drug-drug interactions, as well as patient and clinician preferences, in tailoring anticoagulation for patients with CAT. Anticoagulant therapy should be adapted as the patient's cancer status and management change over time. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|